The digital version of the ASCO Prostate Cancer GUIDELINES contains all the same great information found in the pocket guide, and can be accessed on mobile devices and online:
Subscribe to additional guideline titles for discounted rates
Includes automatic updates during the term of your subscription
CPT® and ICD10 codes can be added to certain guidelines for an additional fee
Supported platforms
iPhone and iPad
Android phones and tablets
Online (internet connection required)
Content on the Guideline Central mobile app accessible without an internet connection
Access to additional guideline summaries, clinical calculators, and more
For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.
For individual use only; contact us for group and site licenses.
The Chemotherapy-Naïve Castration-Resistant Prostate Cancer GUIDELINES Pocket Guide is based on the latest guidelines of the American Society of Clinical Oncology and was developed with their collaboration. It contains key points and a detailed management algorithm.
Bifold
4 Pages
80# Diamond Silk Cover with Satin Aqueous Coating
4.25″ x 7.25″
Key Points
Algorithm for Second-line Hormonal CRPC Treatment
Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.
Men who develop castration-resistant prostate cancer (CRPC) despite castrate levels of testosterone should be maintained in a castrate state indefinitely.
Abiraterone acetate plus prednisone or enzalutamide should be offered for second-line hormonal treatment following first-line hormonal treatment failure for chemotherapy-naïve men who develop CRPC and have radiographic evidence of metastases (M1a/M1s CRPC) because these agents have been shown to significantly increase radiographic progession-free survival (rPFS) and overall survival (OS). (Evidence-based, Strong recommendation)
Palliative care should be offered to all chemotherapy-naïve men with M1 CRPC, particularly those exhibiting symptoms or decreased QOL.
For chemotherapy-naïve patients with M0 CRCP at high risk of developing metastases (rapid PSA doubling time or velocity), second-line hormonal therapies which lower PSA values or slow the rate of rise may be offered, preferably in a clinical trial setting where available, following a discussion with the patient about the limited scientific evidence, potential harms, benefits, cost, and patient preferences.
There are no data to support the use of second-line hormonal therapies for chemotherapy-naïve men with M0 CRPC who are at low risk of developing metastases (low-risk is defined as low PSA and slow PSA doubling time).
Treatment
Algorithm for Second-line Hormonal CRPC Treatment
Want to save this for later? And your free sample to your Library.
Add to Library
Related Pocketcards
To get started, log in or create your free account Create Account
Our Commitment to Our Customer’s Privacy
Thank you for being a user of Guideline Central!
As part of our continued efforts towards protecting your privacy and personal information, we’ve made recent updates to our privacy policy.
By updating our privacy policy with clearer language, our goal is to help you better understand what data we collect and how we use that information.
When we collect your data through site visits and account creation, we agree to never sell that information to third-parties.
This personal information is used solely to provide you a more personalized experience when using the Guideline Central website and app.
At any time, you may opt out of tracking or request account deletion.
Please visit our privacy policy page for more information.
